Cue Biopharma (NASDAQ:CUE) Insider Sumita Ray Sells 8,829 Shares

Cue Biopharma, Inc. (NASDAQ:CUE) insider Sumita Ray sold 8,829 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $265,664.61. Following the completion of the transaction, the insider directly owned 118,545 shares of the company’s stock, valued at $3,567,019.05. The trade was a 6.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Stock Performance

Shares of CUE stock opened at $27.64 on Tuesday. The stock has a fifty day moving average price of $29.47 and a 200 day moving average price of $143.72. The stock has a market cap of $116.09 million, a PE ratio of -1.02 and a beta of 2.47. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.The firm had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million.

Analyst Ratings Changes

A number of equities research analysts recently commented on CUE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research note on Thursday. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma currently has an average rating of “Sell”.

Institutional Trading of Cue Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP purchased a new position in shares of Cue Biopharma in the 2nd quarter worth $337,755,000. Bank of America Corp DE acquired a new position in Cue Biopharma in the second quarter valued at $219,000. ADAR1 Capital Management LLC purchased a new stake in Cue Biopharma during the second quarter valued at about $1,742,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Cue Biopharma during the second quarter valued at about $83,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cue Biopharma during the second quarter worth about $722,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.